Seeking Alpha Bullishness Meets DeepValue Caution on Cardinal Health

What happened

A Seeking Alpha article reiterated a Buy on Cardinal Health, citing robust FY2026 results including 14% revenue growth, 20% gross margin expansion, and doubled free cash flow, along with credible FY2027 guidance for 13-15% non-GAAP EPS growth. However, the latest DeepValue master report rates CAH a 'POTENTIAL SELL' with conviction 4.0, arguing that the stock is overvalued at roughly 22x forward non-GAAP EPS with negative book equity and a widening GAAP-to-non-GAAP earnings gap. The report highlights that earnings quality is increasingly acquisition-adjusted, with $464M in amortization and $126M in acquisition-related compensation in FY25, plus customer concentration (CVS at ~30% of revenue) and IRA drug-pricing risks. Despite the article's optimism, the master report suggests trimming above $235 and waiting for an entry near $185, indicating the market may be pricing in flawless execution with little margin of safety.

Implication

The positive headline numbers rely heavily on non-GAAP adjustments, which mask rising acquisition costs and a balance sheet burdened by $5.5B in net debt and negative equity. At the current price, CAH trades at roughly 32x trailing GAAP EPS and 22x the FY26 non-GAAP floor, leaving limited upside if growth normalizes to high-single digits in FY27. The master report's base case values the stock at $205, suggesting it is already slightly overvalued, while the bear case of $165 reflects regulatory and integration risks not adequately priced in. Momentum-driven sentiment, evidenced by record highs and bullish media coverage, increases the risk of sharp de-rating if any guidance wobble occurs, especially given CVS concentration and IRA headwinds. Investors should use strength to reduce positions above $235 and only consider adding back near $185, while monitoring quarterly GAAP versus non-GAAP EPS divergence and MSO integration stress.

Thesis delta

The Seeking Alpha article's positive tone does not alter the DeepValue master report's cautious stance. While FY2026 results and FY2027 guidance are respectable, the valuation already embeds sustained double-digit growth and flawless execution, leaving an asymmetric risk/reward. The thesis remains to lighten into strength rather than add, as the article's bullishness appears based on non-GAAP metrics that understate intrinsic earnings quality concerns.